Analysts forecast that Leap Therapeutics Inc (NASDAQ:LPTX) will post earnings of ($0.48) per share for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for Leap Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.46) and the lowest estimate coming in at ($0.49). Leap Therapeutics posted earnings per share of ($0.74) during the same quarter last year, which indicates a positive year-over-year growth rate of 35.1%. The firm is expected to announce its next quarterly earnings report on Friday, August 10th.
According to Zacks, analysts expect that Leap Therapeutics will report full-year earnings of ($2.23) per share for the current year, with EPS estimates ranging from ($2.38) to ($2.03). For the next fiscal year, analysts anticipate that the business will report earnings of ($1.75) per share, with EPS estimates ranging from ($1.87) to ($1.52). Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for Leap Therapeutics.
Leap Therapeutics (NASDAQ:LPTX) last released its earnings results on Friday, May 11th. The company reported ($0.85) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.61) by ($0.24).
Leap Therapeutics traded down $0.10, reaching $8.13, during trading on Monday, according to Marketbeat. The company’s stock had a trading volume of 27,130 shares, compared to its average volume of 61,836. Leap Therapeutics has a 1 year low of $4.90 and a 1 year high of $10.25. The firm has a market capitalization of $119.34 million, a price-to-earnings ratio of -2.46 and a beta of 0.35.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Millennium Management LLC acquired a new stake in shares of Leap Therapeutics during the 1st quarter worth approximately $105,000. Spark Investment Management LLC acquired a new stake in shares of Leap Therapeutics during the 1st quarter worth approximately $146,000. Point72 Asset Management L.P. acquired a new stake in shares of Leap Therapeutics during the 1st quarter worth approximately $227,000. JPMorgan Chase & Co. increased its holdings in shares of Leap Therapeutics by 39,223.3% during the 1st quarter. JPMorgan Chase & Co. now owns 40,503 shares of the company’s stock worth $336,000 after buying an additional 40,400 shares during the last quarter. Finally, Sabby Management LLC acquired a new stake in shares of Leap Therapeutics during the 4th quarter worth approximately $558,000. Institutional investors and hedge funds own 17.03% of the company’s stock.
About Leap Therapeutics
Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. The company's clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.